Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TriMix DC

Next Previous
Search
Drug Profile

TriMix DC

Alternative Names: TriMixDC

Latest Information Update: 27 Jul 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator eTheRNA Immunotherapies
  • Developer Radbound University Nijmegen; Vrije Universiteit Brussel
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Malignant melanoma; Multiple myeloma

Most Recent Events

  • 27 Jul 2017 Vrije Universiteit Brussel has patent protection for TriMiX technology in USA and Europe
  • 12 Jul 2017 Suspended - Phase-II for Malignant melanoma (Late-stage disease) in Netherlands (Intralymphatic) (eTheRNA website, July 2017)
  • 12 Jul 2017 TriMix-DC is available for licensing as of 12 Jul 2017. http://www.etherna.be (eTheRNA website, July 2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top